2019
DOI: 10.1089/hum.2018.197
|View full text |Cite
|
Sign up to set email alerts
|

Salmeterol with Liver Depot Gene Therapy Enhances the Skeletal Muscle Response in Murine Pompe Disease

Abstract: Gene therapy for Pompe disease with adeno-associated virus (AAV) vectors has advanced into early phase clinical trials; however, the paucity of cation-independent mannose-6-phosphate receptor (CI-MPR) in skeletal muscle, where it is needed to take up acid a-glucosidase (GAA), has impeded the efficacy of Pompe disease gene therapy. Long-acting selective b2 receptor agonists previously enhanced the CI-MPR expression in muscle. In this study we have evaluated the selective b2 agonist salmeterol in GAA knockout mi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
7
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 12 publications
(7 citation statements)
references
References 39 publications
0
7
0
Order By: Relevance
“…Another long-acting β 2 agonist, salmeterol, improved the cardiac response to the direct transduction of striated muscle 33 . Furthermore, salmeterol improved the biochemical correction of skeletal muscle and enhanced muscle strength in combination with liver depot gene therapy 34 . Although direct transduction of muscle might provide more stable transduction, an AAV vector containing a muscle-specific promoter provoked antibody responses that interfered with the uptake of GAA in uncorrected myofibers 35 .…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Another long-acting β 2 agonist, salmeterol, improved the cardiac response to the direct transduction of striated muscle 33 . Furthermore, salmeterol improved the biochemical correction of skeletal muscle and enhanced muscle strength in combination with liver depot gene therapy 34 . Although direct transduction of muscle might provide more stable transduction, an AAV vector containing a muscle-specific promoter provoked antibody responses that interfered with the uptake of GAA in uncorrected myofibers 35 .…”
Section: Discussionmentioning
confidence: 99%
“…33 Furthermore, salmeterol improved the biochemical correction of skeletal muscle and enhanced muscle strength in combination with liver depot gene therapy. 34 Although direct transduction of muscle might provide more stable transduction, an AAV vector containing a muscle-specific promoter provoked antibody responses that interfered with the uptake of GAA in uncorrected myofibers. 35 Immunosuppression was beneficial, because glycogen clearance was clearly enhanced by treatment with a nondepleting anti-CD4 monoclonal antibody along with GAA expression in cardiac muscle.…”
Section: Discussionmentioning
confidence: 99%
“…More recently, to address the poor biodistribution of the agent to certain organs, including CNS studies on modifying the ERT agent have emerged (Condori et al, 2016 ) and skeletal muscle (Koeberl et al, 2011 ; Peng et al, 2017 ; Han et al, 2019 ). To investigate the potential of large-molecular weight compounds to treat neurological disorders, novel approaches are required to surmount the BBB.…”
Section: Perspectives On the Cns-targeting Therapies And Their Limitamentioning
confidence: 99%
“…For muscle targeted systemic gene transfer, various studies using different AAV and different muscle promoters have been performed [ 156 , 159 , 160 , 161 , 162 , 163 , 164 ] in 6 neo /6 neo mice leading to similar findings of improvement of the respiratory phenotype, muscle strength and morphology, although there was not a complete glycogen correction and not in all studies [ 165 ]. For liver targeted systemic transfer various studies using different AAV and liver-specific promoters have been tried too in mice models, showing an efficient liver transduction with 10 to 100 times lower AAV vector doses needed [ 147 , 148 , 152 , 166 , 167 , 168 , 169 , 170 , 171 , 172 ]. In this case, the effects are mainly based on cross-correction, as GAA enzyme is only produced by hepatocytes, secreted to the circulation and taken up by target cells, showing a glycogen clearance in the heart and diaphragm but not as much in the skeletal muscle probably due to an insufficient native secretion of GAA.…”
Section: Glycogen Storage Diseasesmentioning
confidence: 99%